USE OF METHOPYRAPONE (SU-4885) IN THE STUDY OF PITUITARY-ADRENAL RESPONSE IN PATIENTS UNDER CORTICOSTEROID TREATMENT.
D015065:17-Hydroxycorticosteroids; D000305:Adrenal Cortex Hormones; D000311:Adrenal Glands; D000324:Adrenocorticotropic Hormone; D003480:Cushing Syndrome; D004358:Drug Therapy; D007659:Ketones; D008797:Metyrapone; D000451:Mineralocorticoid Receptor Antagonists; D010600:Pharmacology; D010827:Physiology; D010900:Pituitary Diseases; D010902:Pituitary Gland; D014116:Toxicology; D014556:Urine
D015065:17-Hydroxycorticosteroids; D000305:Adrenal Cortex Hormones; D007659:Ketones; D000451:Mineralocorticoid Receptor Antagonists; D000324:Adrenocorticotropic Hormone; D008797:Metyrapone
17-HYDROXYCORTICOSTEROIDS; ADRENAL CORTEX HORMONES; ADRENAL GLANDS; ALDOSTERONE ANTAGONISTS; CORTICOTROPIN; CUSHING'S SYNDROME; DRUG THERAPY; KETONES; METYRAPONE; PHARMACOLOGY; PHYSIOLOGY; PITUITARY GLAND; TOXICOLOGIC REPORT; URINE